Pharma Fraud
This archive displays posts tagged as relevant to pharmaceutical fraud. You may also be interested in our pages:
Question of the Week — Should Drug Companies that Defraud the Government Lose Their Patents?
Posted 09/18/19
September 18, 2019
Florida-based compounding pharmacy Diabetic Care Rx LLC, also known as Patient Care America, together with two of its executives, CEO Patrick Smith and VP of Operations Matthew Smith, and the private equity firm Riordan, Lewis & Haden Inc., will pay $21.36 million to resolve a case brought by two whistleblowers under the False Claims Act alleging that they paid unlawful kickbacks to secure referrals for patients covered by TRICARE, the federal healthcare program that covers military members and their families. The pharmacy paid patient recruiters to target military members and their families for the prescription of compounded creams and vitamins formulated to ensure the highest possible reimbursement from TRICARE. The marketers in turn paid doctors who issued the prescriptions, often without seeing or even speaking to the purported patients. In addition, the pharmacy and marketing company often covered patient copayments through a sham charitable organization affiliated with the marketing company. Private equity investor RLH was alleged to have known about and agreed to the kickback scheme. Whistleblowers Marisela Medrano and Ada Lopez were, respectively, the former Director of Marketing and the Reimbursement Services Manager of PCA. They will receive a yet-to-be-determined share of the U.S. recovery. DOJ; SD FLCatch of the Week – Mallinckrodt Pays for Kickbacks on Acthar; Investigation into Copayment Subsidies Continues
Posted 09/6/19
AKS Allegations
Two whistleblower lawsuits brought under the False Claims Act against Mallinckrodt alleged that from 2009 to 2013, the pharma company, then known as Questcor,...September 5, 2019
El Paso Integrated Physicians Group, P.A., several physicians in the group, and Accutrack Medical Claims Services, LLC, have agreed to pay $2.93 million to resolve a False Claims Act case filed by whistleblower Sergio Garcia alleging that they double-billed and over-billed government payors for the infusion drug Remicade (Infiximab). Remicade is sold in single-use vials; defendants were alleged to have pooled Remicade from partially-used vials, diluted Remicade, and illegally imported drugs from Canada and other foreign countries. USAO WD TexSeptember 5, 2019
In yet another enforcement action relating to a nationwide compounding pharmacy fraud scheme involving OK Compounding, Dr. James Womack of Missouri has agreed to pay $471,221 to resolve his liability under the False Claims Act. Womack allegedly accepting kickbacks disguised as medical director fees in exchange for prescribing medically unnecessary pain creams. USAO NDOKSeptember 4, 2019
Pharmaceutical company Mallinckrodt ARD LLC has agreed to pay $15.4 million to settle allegations of violating the Anti-Kickback Statute by “wining and dining” healthcare providers to induce Medicare prescriptions of its drug H.P. Acthar Gel. The allegations arose from two whistleblowers, who will jointly receive about $2.9 million of the settlement. DOJQuestion of the Week — Is the use of public nuisance law against J&J for its role in the opioid crisis appropriate?
Posted 08/29/19
Question of the Week — Should Pharmacy Benefit Managers (PBMs) be allowed to deny patients access to essential life-saving drugs prescribed by their doctor?
Posted 08/19/19
Question of the Week — Will Healthcare Settlements Continue to Dominate False Claims Act Recoveries?
Posted 07/24/19
